

# Michael Baumann

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6865012/publications.pdf>

Version: 2024-02-01

342  
papers

15,841  
citations

15466

65  
h-index

25716

108  
g-index

371  
all docs

371  
docs citations

371  
times ranked

16927  
citing authors

#	ARTICLE	IF	CITATIONS
1	Exploring the role of cancer stem cells in radioresistance. <i>Nature Reviews Cancer</i> , 2008, 8, 545-554.	12.8	766
2	Expanding global access to radiotherapy. <i>Lancet Oncology</i> , The, 2015, 16, 1153-1186.	5.1	709
3	Radiation oncology in the era of precision medicine. <i>Nature Reviews Cancer</i> , 2016, 16, 234-249.	12.8	636
4	Hyperfractionated Accelerated Chemoradiation With Concurrent Fluorouracil-Mitomycin Is More Effective Than Dose-Escalated Hyperfractionated Accelerated Radiation Therapy Alone in Locally Advanced Head and Neck Cancer: Final Results of the Radiotherapy Cooperative Clinical Trials Group of the German Cancer Society 95-06 Prospective Randomized Trial. <i>Journal of Clinical Oncology</i> , 2005, 23, 1125-1135.	0.8	269
5	Caring for patients with cancer in the COVID-19 era. <i>Nature Medicine</i> , 2020, 26, 665-671.	15.2	269
6	Exploratory prospective trial of hypoxia-specific PET imaging during radiochemotherapy in patients with locally advanced head-and-neck cancer. <i>Radiotherapy and Oncology</i> , 2012, 105, 21-28.	0.3	262
7	Cancer stem cells: Radioresistance, prediction of radiotherapy outcome and specific targets for combined treatments. <i>Advanced Drug Delivery Reviews</i> , 2017, 109, 63-73.	6.6	247
8	Hyperfractionated or Accelerated Radiotherapy in Lung Cancer: An Individual Patient Data Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2012, 30, 2788-2797.	0.8	227
9	First clinical application of a prompt gamma based in vivo proton range verification system. <i>Radiotherapy and Oncology</i> , 2016, 118, 232-237.	0.3	208
10	Blockage of Epidermal Growth Factor Receptor-Phosphatidylinositol 3-Kinase-AKT Signaling Increases Radiosensitivity of K-RAS Mutated Human Tumor Cells In vitro by Affecting DNA Repair. <i>Clinical Cancer Research</i> , 2006, 12, 4119-4126.	3.2	196
11	Aldehyde Dehydrogenase Is Regulated by $\beta$ -Catenin/TCF and Promotes Radioresistance in Prostate Cancer Progenitor Cells. <i>Cancer Research</i> , 2015, 75, 1482-1494.	0.4	195
12	$\beta$ 1 Integrin/FAK/cortactin signaling is essential for human head and neck cancer resistance to radiotherapy. <i>Journal of Clinical Investigation</i> , 2012, 122, 1529-1540.	3.9	194
13	CD8+ tumour-infiltrating lymphocytes in relation to HPV status and clinical outcome in patients with head and neck cancer after postoperative chemoradiotherapy: A multicentre study of the German cancer consortium radiation oncology group (DKTK-ROG). <i>International Journal of Cancer</i> , 2016, 138, 171-181.	2.3	184
14	Glycolytic metabolism and tumour response to fractionated irradiation. <i>Radiotherapy and Oncology</i> , 2010, 94, 102-109.	0.3	181
15	EGFR-targeted anti-cancer drugs in radiotherapy: Preclinical evaluation of mechanisms. <i>Radiotherapy and Oncology</i> , 2007, 83, 238-248.	0.3	170
16	A comparative study of machine learning methods for time-to-event survival data for radiomics risk modelling. <i>Scientific Reports</i> , 2017, 7, 13206.	1.6	163
17	Targeting the epidermal growth factor receptor in radiotherapy: radiobiological mechanisms, preclinical and clinical results. <i>Radiotherapy and Oncology</i> , 2004, 72, 257-266.	0.3	161
18	Discovery of the cancer stem cell related determinants of radioresistance. <i>Radiotherapy and Oncology</i> , 2013, 108, 378-387.	0.3	159

#	ARTICLE	IF	CITATIONS
19	Tumor lactate content predicts for response to fractionated irradiation of human squamous cell carcinomas in nude mice. <i>Radiotherapy and Oncology</i> , 2006, 81, 130-135.	0.3	158
20	Radiotheranostics: a roadmap for future development. <i>Lancet Oncology</i> , The, 2020, 21, e146-e156.	5.1	151
21	Pre-treatment number of clonogenic cells and their radiosensitivity are major determinants of local tumour control after fractionated irradiation. <i>Radiotherapy and Oncology</i> , 2007, 83, 304-310.	0.3	144
22	HPV16 DNA status is a strong prognosticator of loco-regional control after postoperative radiochemotherapy of locally advanced oropharyngeal carcinoma: Results from a multicentre explorative study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). <i>Radiotherapy and Oncology</i> , 2014, 113, 317-323.	0.3	141
23	Radioresistance of K-Ras mutated human tumor cells is mediated through EGFR-dependent activation of PI3K-AKT pathway. <i>Radiotherapy and Oncology</i> , 2005, 76, 143-150.	0.3	133
24	HPV status, cancer stem cell marker expression, hypoxia gene signatures and tumour volume identify good prognosis subgroups in patients with HNSCC after primary radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). <i>Radiotherapy and Oncology</i> , 2016, 121, 364-373.	0.3	130
25	Low Cancer Stem Cell Marker Expression and Low Hypoxia Identify Good Prognosis Subgroups in HPV(+) HNSCC after Postoperative Radiochemotherapy: A Multicenter Study of the DKTK-ROG. <i>Clinical Cancer Research</i> , 2016, 22, 2639-2649.	3.2	127
26	Residual tumour hypoxia in head-and-neck cancer patients undergoing primary radiochemotherapy, final results of a prospective trial on repeat FMISO-PET imaging. <i>Radiotherapy and Oncology</i> , 2017, 124, 533-540.	0.3	123
27	Hyperbaric oxygen therapy in the treatment of radio-induced lesions in normal tissues: a literature review. <i>Radiotherapy and Oncology</i> , 2004, 72, 1-13.	0.3	116
28	Early FDG PET at 10 or 20 Gy under chemoradiotherapy is prognostic for locoregional control and overall survival in patients with head and neck cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 38, 1203-1211.	3.3	108
29	Combining precision radiotherapy with molecular targeting and immunomodulatory agents: a guideline by the American Society for Radiation Oncology. <i>Lancet Oncology</i> , The, 2018, 19, e240-e251.	5.1	108
30	Cancer Stem Cells: Targets and Potential Biomarkers for Radiotherapy. <i>Clinical Cancer Research</i> , 2011, 17, 7224-7229.	3.2	106
31	EGF Receptor Inhibition Radiosensitizes NSCLC Cells by Inducing Senescence in Cells Sustaining DNA Double-Strand Breaks. <i>Cancer Research</i> , 2011, 71, 6261-6269.	0.4	105
32	Pimonidazole labelling and response to fractionated irradiation of five human squamous cell carcinoma (hSCC) lines in nude mice: The need for a multivariate approach in biomarker studies. <i>Radiotherapy and Oncology</i> , 2006, 81, 122-129.	0.3	102
33	Repopulation of FaDu human squamous cell carcinoma during fractionated radiotherapy correlates with reoxygenation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 51, 483-493.	0.4	101
34	Radiogenomics: Radiobiology Enters the Era of Big Data and Team Science. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 709-713.	0.4	99
35	Clinical Implementation of Dual-energy CT for Proton Treatment Planning on Pseudo-monoenergetic CT scans. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 427-434.	0.4	98
36	Cancer stem cells at the crossroads of current cancer therapy failures—Radiation oncology perspective. <i>Seminars in Cancer Biology</i> , 2010, 20, 116-124.	4.3	97

#	ARTICLE	IF	CITATIONS
37	Response of Human Squamous Cell Carcinoma Xenografts of Different Sizes to Irradiation: Relationship of Clonogenic Cells, Cellular Radiation Sensitivity in Vivo, and Tumor Rescuing Units. <i>Radiation Research</i> , 1990, 123, 325.	0.7	95
38	How Much Does It Cost to Research and Develop a New Drug? A Systematic Review and Assessment. <i>Pharmacoeconomics</i> , 2021, 39, 1243-1269.	1.7	94
39	CD44: A Cancer Stem Cell-Related Biomarker with Predictive Potential for Radiotherapy. <i>Clinical Cancer Research</i> , 2010, 16, 5091-5093.	3.2	93
40	Clinical perspectives of cancer stem cell research in radiation oncology. <i>Radiotherapy and Oncology</i> , 2013, 108, 388-396.	0.3	93
41	Predictive factors in radiotherapy for non-small cell lung cancer: present status. <i>Lung Cancer</i> , 2001, 31, 43-56.	0.9	91
42	The PD-1/PD-L1 axis and human papilloma virus in patients with head and neck cancer after adjuvant chemoradiotherapy: A multicentre study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). <i>International Journal of Cancer</i> , 2017, 141, 594-603.	2.3	91
43	Stimulated PI3K-AKT Signaling Mediated through Ligand or Radiation-Induced EGFR Depends Indirectly, but not Directly, on Constitutive K-Ras Activity. <i>Molecular Cancer Research</i> , 2007, 5, 863-872.	1.5	90
44	Towards genetic prediction of radiation responses: ESTRO's GENEPI project. <i>Radiotherapy and Oncology</i> , 2003, 69, 121-125.	0.3	89
45	Identification of Patient Benefit From Proton Therapy for Advanced Head and Neck Cancer Patients Based on Individual and Subgroup Normal Tissue Complication Probability Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 1165-1174.	0.4	89
46	PINCH1 regulates Akt1 activation and enhances radioresistance by inhibiting PP1. <i>Journal of Clinical Investigation</i> , 2010, 120, 2516-2527.	3.9	89
47	Cancer stem cell related markers of radioresistance in head and neck squamous cell carcinoma. <i>Oncotarget</i> , 2015, 6, 34494-34509.	0.8	88
48	Decreased repopulation as well as increased reoxygenation contribute to the improvement in local control after targeting of the EGFR by C225 during fractionated irradiation. <i>Radiotherapy and Oncology</i> , 2005, 76, 162-167.	0.3	85
49	“Radiobiology of Proton Therapy” Results of an international expert workshop. <i>Radiotherapy and Oncology</i> , 2018, 128, 56-67.	0.3	85
50	Radiosensitization of Ras-mutated human tumor cells in vitro by the specific EGF receptor antagonist BIBX1382BS. <i>Radiotherapy and Oncology</i> , 2005, 74, 117-129.	0.3	84
51	Cancer Stem Cells as a Predictive Factor in Radiotherapy. <i>Seminars in Radiation Oncology</i> , 2012, 22, 151-174.	1.0	83
52	MRI-guided Radiation Therapy: An Emerging Paradigm in Adaptive Radiation Oncology. <i>Radiology</i> , 2021, 298, 248-260.	3.6	83
53	Radiobiological hypoxia, histological parameters of tumour microenvironment and local tumour control after fractionated irradiation. <i>Radiotherapy and Oncology</i> , 2010, 96, 116-122.	0.3	80
54	Radiation Resistance in KRAS-Mutated Lung Cancer Is Enabled by Stem-like Properties Mediated by an Osteopontin-EGFR Pathway. <i>Cancer Research</i> , 2017, 77, 2018-2028.	0.4	80

#	ARTICLE	IF	CITATIONS
55	Creating a data exchange strategy for radiotherapy research: Towards federated databases and anonymised public datasets. <i>Radiotherapy and Oncology</i> , 2014, 113, 303-309.	0.3	79
56	Preclinical evaluation of molecular-targeted anticancer agents for radiotherapy. <i>Radiotherapy and Oncology</i> , 2006, 80, 112-122.	0.3	78
57	Diverse effects of combined radiotherapy and EGFR inhibition with antibodies or TK inhibitors on local tumour control and correlation with EGFR gene expression. <i>Radiotherapy and Oncology</i> , 2011, 99, 323-330.	0.3	78
58	Age-Related Changes in the Frequency of Mesenchymal Stem Cells in the Bone Marrow of Rats. <i>Stem Cells and Development</i> , 2007, 16, 439-446.	1.1	76
59	Cancer stem cells and radiotherapy. <i>International Journal of Radiation Biology</i> , 2009, 85, 391-402.	1.0	75
60	Additional PET/CT in week 5 of radiotherapy for patients with stage III non-small cell lung cancer as a means of dose escalation planning?. <i>Radiotherapy and Oncology</i> , 2008, 88, 335-341.	0.3	74
61	Subjugation of TGF $\beta$ 2 Signaling by Human Papilloma Virus in Head and Neck Squamous Cell Carcinoma Shifts DNA Repair from Homologous Recombination to Alternative End Joining. <i>Clinical Cancer Research</i> , 2018, 24, 6001-6014.	3.2	71
62	In vivo radiation sensitivity of glioblastoma multiforme. <i>International Journal of Radiation Oncology Biology Physics</i> , 1995, 32, 99-104.	0.4	70
63	Prediction of clonogenic cell survival curves based on the number of residual DNA double strand breaks measured by $\gamma$ H2AX staining. <i>International Journal of Radiation Biology</i> , 2009, 85, 1032-1041.	1.0	70
64	Cancer Prevention Europe. <i>Molecular Oncology</i> , 2019, 13, 528-534.	2.1	70
65	GLS-driven glutamine catabolism contributes to prostate cancer radiosensitivity by regulating the redox state, stemness and ATG5-mediated autophagy. <i>Theranostics</i> , 2021, 11, 7844-7868.	4.6	70
66	Individualization of cancer treatment from radiotherapy perspective. <i>Molecular Oncology</i> , 2012, 6, 211-221.	2.1	68
67	Improving the Predictive Value of Preclinical Studies in Support of Radiotherapy Clinical Trials. <i>Clinical Cancer Research</i> , 2016, 22, 3138-3147.	3.2	68
68	Impact of overall treatment time of fractionated irradiation on local control of human FaDu squamous cell carcinoma in nude mice. <i>Radiotherapy and Oncology</i> , 1994, 32, 137-143.	0.3	67
69	A Five-MicroRNA Signature Predicts Survival and Disease Control of Patients with Head and Neck Cancer Negative for HPV Infection. <i>Clinical Cancer Research</i> , 2019, 25, 1505-1516.	3.2	67
70	New anticancer agents: in vitro and in vivo evaluation. <i>In Vivo</i> , 2005, 19, 1-7.	0.6	67
71	Influence of connective tissue diseases on the expression of radiation side effects: A systematic review. <i>Radiotherapy and Oncology</i> , 2006, 78, 123-130.	0.3	66
72	Aberrant overexpression of miR-421 downregulates ATM and leads to a pronounced DSB repair defect and clinical hypersensitivity in SKX squamous cell carcinoma. <i>Radiotherapy and Oncology</i> , 2013, 106, 147-154.	0.3	66

#	ARTICLE	IF	CITATIONS
73	Splicing Mutations in TP53 in Human Squamous Cell Carcinoma Lines Influence Immunohistochemical Detection. <i>Journal of Histochemistry and Cytochemistry</i> , 2002, 50, 197-204.	1.3	64
74	Combination of EGFR/HER2 Tyrosine Kinase Inhibition by BIBW 2992 and BIBW 2669 with Irradiation in FaDu Human Squamous Cell Carcinoma. <i>Strahlentherapie Und Onkologie</i> , 2007, 183, 256-264.	1.0	64
75	Radiolabeled Cetuximab Conjugates for EGFR Targeted Cancer Diagnostics and Therapy. <i>Pharmaceuticals</i> , 2014, 7, 311-338.	1.7	62
76	An Epigenetic Reprogramming Strategy to Resensitize Radioresistant Prostate Cancer Cells. <i>Cancer Research</i> , 2016, 76, 2637-2651.	0.4	62
77	Comparative analysis of transcriptomics based hypoxia signatures in head- and neck squamous cell carcinoma. <i>Radiotherapy and Oncology</i> , 2016, 118, 350-358.	0.3	62
78	Exploratory Study of the Prognostic Value of Microenvironmental Parameters During Fractionated Irradiation in Human Squamous Cell Carcinoma Xenografts. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 1205-1213.	0.4	61
79	EGFR-Mediated Chromatin Condensation Protects KRAS-Mutant Cancer Cells against Ionizing Radiation. <i>Cancer Research</i> , 2014, 74, 2825-2834.	0.4	61
80	Guidelines for equipment and staffing of radiotherapy facilities in the European countries: Final results of the ESTRO-HERO survey. <i>Radiotherapy and Oncology</i> , 2014, 112, 165-177.	0.3	61
81	Effect of increase of radiation dose on local control relates to pre-treatment FDG uptake in FaDu tumours in nude mice. <i>Radiotherapy and Oncology</i> , 2007, 83, 311-315.	0.3	59
82	Prognostic Value of Pretherapeutic Tumor-to-Blood Standardized Uptake Ratio in Patients with Esophageal Carcinoma. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1150-1156.	2.8	59
83	Spatial distribution of FMISO in head and neck squamous cell carcinomas during radio-chemotherapy and its correlation to pattern of failure. <i>Acta Oncologica</i> , 2015, 54, 1355-1363.	0.8	57
84	Enhanced Susceptibility of Irradiated Tumor Vessels to Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibition. <i>Cancer Research</i> , 2005, 65, 5374-5379.	0.4	54
85	PI3K-Akt signaling regulates basal, but MAP-kinase signaling regulates radiation-induced XRCC1 expression in human tumor cells in vitro. <i>DNA Repair</i> , 2008, 7, 1746-1756.	1.3	54
86	Response of xenografts of human malignant gliomas and squamous cell carcinomas to fractionated irradiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 1992, 23, 803-809.	0.4	53
87	The CD98 Heavy Chain Is a Marker and Regulator of Head and Neck Squamous Cell Carcinoma Radiosensitivity. <i>Clinical Cancer Research</i> , 2019, 25, 3152-3163.	3.2	53
88	The results of colorectal cancer treatment by p53 status. <i>Diseases of the Colon and Rectum</i> , 2001, 44, 322-333.	0.7	52
89	EGFR-TK inhibition before radiotherapy reduces tumour volume but does not improve local control: Differential response of cancer stem cells and nontumourigenic cells?. <i>Radiotherapy and Oncology</i> , 2007, 83, 316-325.	0.3	51
90	Radiobiological Effectiveness of Laser Accelerated Electrons in Comparison to Electron Beams from a Conventional Linear Accelerator. <i>Journal of Radiation Research</i> , 2012, 53, 395-403.	0.8	50

#	ARTICLE	IF	CITATIONS
91	BAY 87â€“2243, a novel inhibitor of hypoxia-induced gene activation, improves local tumor control after fractionated irradiation in a schedule-dependent manner in head and neck human xenografts. <i>Radiation Oncology</i> , 2014, 9, 207.	1.2	50
92	Heat shock protein 70 and tumorâ€“infiltrating NK cells as prognostic indicators for patients with squamous cell carcinoma of the head and neck after radiochemotherapy: A multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group (DKTKâ€“ROG). <i>International Journal of Cancer</i> , 2018, 142, 1911-1925.	2.3	50
93	CD133 expression is not selective for tumor-initiating or radioresistant cell populations in the CRC cell lines HCT-116. <i>Radiotherapy and Oncology</i> , 2009, 92, 353-361.	0.3	49
94	ErbB2 expression through heterodimerization with erbB1 is necessary for ionizing radiation- but not EGF-induced activation of Akt survival pathway. <i>Radiotherapy and Oncology</i> , 2010, 97, 338-345.	0.3	49
95	GTV differentially impacts locoregional control of non-small cell lung cancer (NSCLC) after different fractionation schedules: Subgroup analysis of the prospective randomized CHARTWEL trial. <i>Radiotherapy and Oncology</i> , 2013, 106, 299-304.	0.3	49
96	Radiolabeled anti-EGFR-antibody improves local tumor control after external beam radiotherapy and offers theragnostic potential. <i>Radiotherapy and Oncology</i> , 2014, 110, 362-369.	0.3	49
97	The extreme radiosensitivity of the squamous cell carcinoma SKX is due to a defect in double-strand break repair. <i>Radiotherapy and Oncology</i> , 2009, 90, 257-264.	0.3	48
98	Photon vs. proton radiochemotherapy: Effects on brain tissue volume and perfusion. <i>Radiotherapy and Oncology</i> , 2018, 128, 121-127.	0.3	48
99	Expressing cytotoxic compounds in <i>Escherichia coli</i> Nissle 1917 for tumor-targeting therapy. <i>Research in Microbiology</i> , 2019, 170, 74-79.	1.0	48
100	Radiosensitization of NSCLC cells by EGFR inhibition is the result of an enhanced p53-dependent G1 arrest. <i>Radiotherapy and Oncology</i> , 2015, 115, 120-127.	0.3	47
101	Impact of adjuvant inhibition of vascular endothelial growth factor receptor tyrosine kinases on tumor growth delay and local tumor control after fractionated irradiation in human squamous cell carcinomas in nude mice. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 61, 908-914.	0.4	46
102	An investigation of the relation between tumor-to-liver ratio (TLR) and tumor-to-blood standard uptake ratio (SUR) in oncological FDG PET. <i>EJNMMI Research</i> , 2016, 6, 19.	1.1	46
103	Hyperfractionated radiotherapy in head and neck cancer: a second look at the clinical data. <i>Radiotherapy and Oncology</i> , 1998, 46, 127-130.	0.3	45
104	Development and Validation of a Gene Signature for Patients with Head and Neck Carcinomas Treated by Postoperative Radio(chemo)therapy. <i>Clinical Cancer Research</i> , 2018, 24, 1364-1374.	3.2	45
105	CT imaging during treatment improves radiomic models for patients with locally advanced head and neck cancer. <i>Radiotherapy and Oncology</i> , 2019, 130, 10-17.	0.3	44
106	Response of U87 glioma xenografts treated with concurrent rapamycin and fractionated radiotherapy: Possible role for thrombosis. <i>Radiotherapy and Oncology</i> , 2007, 82, 96-104.	0.3	43
107	Co-localisation of hypoxia and perfusion markers with parameters of glucose metabolism in human squamous cell carcinoma (hSCC) xenografts. <i>International Journal of Radiation Biology</i> , 2009, 85, 972-980.	1.0	43
108	Experimental study on different combination schedules of VEGF-receptor inhibitor PTK787/ZK222584 and fractionated irradiation. <i>Anticancer Research</i> , 2003, 23, 3869-76.	0.5	43

#	ARTICLE	IF	CITATIONS
109	Increased evidence for the prognostic value of primary tumor asphericity in pretherapeutic FDG PET for risk stratification in patients with head and neck cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 429-437.	3.3	42
110	Individual patient data meta-analysis of FMISO and FAZA hypoxia PET scans from head and neck cancer patients undergoing definitive radio-chemotherapy. <i>Radiotherapy and Oncology</i> , 2020, 149, 189-196.	0.3	41
111	Does heterogeneity of pimonidazole labelling correspond to the heterogeneity of radiation-response of FaDu human squamous cell carcinoma?. <i>Radiotherapy and Oncology</i> , 2005, 76, 206-212.	0.3	40
112	Serial FDG-PET on patients with head and neck cancer: Implications for radiation therapy. <i>International Journal of Radiation Biology</i> , 2009, 85, 796-804.	1.0	40
113	Residual DNA double strand breaks in perfused but not in unperfused areas determine different radiosensitivity of tumours. <i>Radiotherapy and Oncology</i> , 2011, 100, 137-144.	0.3	40
114	Effect of irradiated volume on lung damage in pigs. <i>Radiotherapy and Oncology</i> , 1997, 44, 35-40.	0.3	39
115	Antiproliferative effects of EGFR tyrosine kinase inhibition and radiation-induced genotoxic injury are attenuated by adhesion to fibronectin. <i>Radiotherapy and Oncology</i> , 2006, 80, 178-184.	0.3	39
116	Precise image-guided irradiation of small animals: a flexible non-profit platform. <i>Physics in Medicine and Biology</i> , 2016, 61, 3084-3108.	1.6	39
117	Heterogeneity of tumour response to combined radiotherapy and EGFR inhibitors: Differences between antibodies and TK inhibitors. <i>International Journal of Radiation Biology</i> , 2009, 85, 943-954.	1.0	38
118	Cellular and Tumor Radiosensitivity is Correlated to Epidermal Growth Factor Receptor Protein Expression Level in Tumors Without EGFR Amplification. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 1181-1188.	0.4	38
119	$\hat{H}2AX$ assay in ex vivo irradiated tumour specimens: A novel method to determine tumour radiation sensitivity in patient-derived material. <i>Radiotherapy and Oncology</i> , 2015, 116, 473-479.	0.3	38
120	Electronic real-time assessment of patient-reported outcomes in routine care—first findings and experiences from the implementation in a comprehensive cancer center. <i>Supportive Care in Cancer</i> , 2016, 24, 3047-56.	1.0	38
121	Cancer Core Europe: A translational research infrastructure for a European mission on cancer. <i>Molecular Oncology</i> , 2019, 13, 521-527.	2.1	38
122	2-Deoxy-2-[ $^{18}F$ ]Fluoro-D-Glucose Positron Emission Tomography in Target Volume Definition for Radiotherapy of Patients with Non-Small-Cell Lung Cancer. <i>Molecular Imaging and Biology</i> , 2002, 4, 257-263.	1.3	37
123	Residual $\hat{H}2AX$ foci predict local tumour control after radiotherapy. <i>Radiotherapy and Oncology</i> , 2013, 108, 434-439.	0.3	37
124	Hyperfractionated Accelerated Radiation Therapy (HART) of 70.6 Gy With Concurrent 5-FU/Mitomycin C Is Superior to HART of 77.6 Gy Alone in Locally Advanced Head and Neck Cancer: Long-term Results of the ARO 95-06 Randomized Phase III Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 916-924.	0.4	37
125	Residual $\hat{H}2AX$ foci after ex vivo irradiation of patient samples with known tumour-type specific differences in radio-responsiveness. <i>Radiotherapy and Oncology</i> , 2015, 116, 480-485.	0.3	37
126	Independent validation of a new reirradiation risk score (RRRS) for glioma patients predicting post-recurrence survival: A multicenter DKTK/ROG analysis. <i>Radiotherapy and Oncology</i> , 2018, 127, 121-127.	0.3	37



#	ARTICLE	IF	CITATIONS
127	Prognostic Value of Radiobiological Hypoxia during Fractionated Irradiation for Local Tumor Control. <i>Strahlentherapie Und Onkologie</i> , 2011, 187, 306-310.	1.0	36
128	Impact of waiting time after surgery and overall time of postoperative radiochemotherapy on treatment outcome in glioblastoma multiforme. <i>Radiation Oncology</i> , 2015, 10, 172.	1.2	36
129	Global Task Force on Radiotherapy for Cancer Control. <i>Lancet Oncology, The</i> , 2015, 16, 1144-1146.	5.1	36
130	NTCP reduction for advanced head and neck cancer patients using proton therapy for complete or sequential boost treatment versus photon therapy. <i>Acta Oncologica</i> , 2015, 54, 1658-1664.	0.8	36
131	Can Local Ablative Radiotherapy Revert Castration-resistant Prostate Cancer to an Earlier Stage of Disease?. <i>European Urology</i> , 2019, 75, 548-551.	0.9	36
132	Radioresistance of KRAS/TP53-mutated lung cancer can be overcome by radiation dose escalation or EGFR tyrosine kinase inhibition in vivo. <i>International Journal of Cancer</i> , 2020, 147, 472-477.	2.3	36
133	Low-dose hyperradiosensitivity of human glioblastoma cell lines in vitro does not translate into improved outcome of ultrafractionated radiotherapy in vivo. <i>International Journal of Radiation Biology</i> , 2005, 81, 751-758.	1.0	35
134	Time in radiation oncology – Keep it short!. <i>Radiotherapy and Oncology</i> , 2013, 106, 271-275.	0.3	34
135	Effect of [18F]FMISO stratified dose-escalation on local control in FaDu hSCC in nude mice. <i>Radiotherapy and Oncology</i> , 2014, 111, 81-87.	0.3	34
136	Re-irradiation of recurrent gliomas: pooled analysis and validation of an established prognostic score – report of the Radiation Oncology Group (<sc>ROG</sc>) of the German Cancer Consortium (<sc>DKTK</sc>). <i>Cancer Medicine</i> , 2018, 7, 1742-1749.	1.3	34
137	FLASH radiotherapy International Workshop. <i>Radiotherapy and Oncology</i> , 2019, 139, 1-3.	0.3	34
138	2D and 3D convolutional neural networks for outcome modelling of locally advanced head and neck squamous cell carcinoma. <i>Scientific Reports</i> , 2020, 10, 15625.	1.6	34
139	The translational research chain: is it delivering the goods?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2001, 49, 345-351.	0.4	33
140	Towards a cancer mission in Horizon Europe: recommendations. <i>Molecular Oncology</i> , 2020, 14, 1589-1615.	2.1	33
141	CD133 expression is not selective for tumor-initiating or radioresistant cell populations in the CRC cell line HCT-116. <i>Radiotherapy and Oncology</i> , 2010, 94, 375-383.	0.3	32
142	Independent validation of tumour volume, cancer stem cell markers and hypoxia-associated gene expressions for HNSCC after primary radiochemotherapy. <i>Clinical and Translational Radiation Oncology</i> , 2019, 16, 40-47.	0.9	32
143	Pharmacological inhibition of EGFR tyrosine kinase affects ILK-mediated cellular radiosensitization in vitro. <i>International Journal of Radiation Biology</i> , 2007, 83, 793-802.	1.0	29
144	Hypoxia-Inducible Factor Pathway Inhibition Resolves Tumor Hypoxia and Improves Local Tumor Control After Single-Dose Irradiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 159-166.	0.4	29

#	ARTICLE	IF	CITATIONS
145	Effect of cetuximab and fractionated irradiation on tumour micro-environment. <i>Radiotherapy and Oncology</i> , 2010, 97, 322-329.	0.3	28
146	Dose and fractionation concepts in the primary radiotherapy of non-small cell lung cancer. <i>Lung Cancer</i> , 2001, 33, S35-S45.	0.9	27
147	Kinetics of EGFR expression during fractionated irradiation varies between different human squamous cell carcinoma lines in nude mice. <i>Radiotherapy and Oncology</i> , 2005, 76, 151-156.	0.3	27
148	Effects of Lovastatin Alone or Combined with Irradiation on Tumor Cells in Vitro and in Vivo. <i>Strahlentherapie Und Onkologie</i> , 2008, 184, 48-53.	1.0	27
149	Comparison study of in vivo dose response to laser-driven versus conventional electron beam. <i>Radiation and Environmental Biophysics</i> , 2015, 54, 155-166.	0.6	27
150	Development and validation of NTCP models for acute side-effects resulting from proton beam therapy of brain tumours. <i>Radiotherapy and Oncology</i> , 2019, 130, 164-171.	0.3	27
151	Oct4 confers stemness and radioresistance to head and neck squamous cell carcinoma by regulating the homologous recombination factors PSMC3IP and RAD54L. <i>Oncogene</i> , 2021, 40, 4214-4228.	2.6	27
152	Clinical biomarkers of kinase activity: examples from EGFR inhibition trials. <i>Cancer and Metastasis Reviews</i> , 2008, 27, 387-402.	2.7	26
153	Epidermal growth factor receptor inhibitors for radiotherapy: biological rationale and preclinical results. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 60, 1019-1028.	1.2	26
154	Combined treatment of the immunoconjugate bivatuzumab mertansine and fractionated irradiation improves local tumour control in vivo. <i>Radiotherapy and Oncology</i> , 2012, 102, 444-449.	0.3	26
155	Research Facility for Radiobiological Studies at the University Proton Therapy Dresden. <i>International Journal of Particle Therapy</i> , 2018, 5, 172-182.	0.9	26
156	Toxicity and Efficacy of Local Ablative, Image-guided Radiotherapy in Gallium-68 Prostate-specific Membrane Antigen Targeted Positron Emission Tomography <sup>+</sup> staged, Castration-sensitive Oligometastatic Prostate Cancer: The OLI-P Phase 2 Clinical Trial. <i>European Urology Oncology</i> , 2022, 5, 44-51.	2.6	26
157	Rat model of lung fibrosis: comparison of functional, biochemical, and histopathological changes 4 months after single irradiation of the right hemithorax. <i>Toxicology</i> , 2001, 161, 153-163.	2.0	25
158	Radiobiological Hypoxia, Oxygen Tension, Interstitial Fluid Pressure and Relative Viable Tumour Area in Two Human Squamous Cell Carcinomas in Nude Mice During Fractionated Radiotherapy. <i>Acta Oncologica</i> , 2001, 40, 519-528.	0.8	25
159	Impact of robust treatment planning on single- and multi-field optimized plans for proton beam therapy of unilateral head and neck target volumes. <i>Radiation Oncology</i> , 2017, 12, 190.	1.2	25
160	Repeat FMISO-PET imaging weakly correlates with hypoxia-associated gene expressions for locally advanced HNSCC treated by primary radiochemotherapy. <i>Radiotherapy and Oncology</i> , 2019, 135, 43-50.	0.3	25
161	TCP and NTCP: a basic introduction. <i>Rays</i> , 2005, 30, 99-104.	0.2	25
162	Impact of overall treatment time on local control of slow growing human GL squamous cell carcinoma in nude mice treated by fractionated irradiation. <i>Radiotherapy and Oncology</i> , 1999, 50, 107-111.	0.3	24

#	ARTICLE	IF	CITATIONS
163	Immunohistochemically Detected p53 Mutations in Epithelial Tumors and Results of Treatment with Chemotherapy and Radiotherapy. <i>Strahlentherapie Und Onkologie</i> , 2002, 178, 411-421.	1.0	24
164	Radiotherapy of lung cancer: Technology meets biology meets multidisciplinary. <i>Radiotherapy and Oncology</i> , 2009, 91, 279-281.	0.3	24
165	Fractionation in prostate cancer – Is it time after all?. <i>Radiotherapy and Oncology</i> , 2010, 96, 1-5.	0.3	24
166	Quantitative modifications of TNM staging, clinical staging and therapeutic intent by FDG-PET/CT in patients with non small cell lung cancer scheduled for radiotherapy – A retrospective study. <i>Lung Cancer</i> , 2012, 78, 148-152.	0.9	24
167	SDF-1/CXCR4 expression is an independent negative prognostic biomarker in patients with head and neck cancer after primary radiochemotherapy. <i>Radiotherapy and Oncology</i> , 2018, 126, 125-131.	0.3	24
168	Cancer stem cells in radiation response: current views and future perspectives in radiation oncology. <i>International Journal of Radiation Biology</i> , 2019, 95, 900-911.	1.0	24
169	Neurocognitive function and quality of life after proton beam therapy for brain tumour patients. <i>Radiotherapy and Oncology</i> , 2020, 143, 108-116.	0.3	24
170	Molecular targeting in radiotherapy of lung cancer. <i>Lung Cancer</i> , 2004, 45, S187-S197.	0.9	23
171	First report on the patient database for the identification of the genetic pathways involved in patients over-reacting to radiotherapy: GENEPII. <i>Radiotherapy and Oncology</i> , 2010, 97, 36-39.	0.3	23
172	Prognostic Value of Standardized Uptake Ratio in Patients with Trimodality Treatment of Locally Advanced Esophageal Carcinoma. <i>Journal of Nuclear Medicine</i> , 2019, 60, 192-198.	2.8	23
173	Triple angiokinase inhibition, tumour hypoxia and radiation response of FaDu human squamous cell carcinomas. <i>Radiotherapy and Oncology</i> , 2009, 92, 405-410.	0.3	22
174	SABR in NSCLC – The beginning of the end or the end of the beginning?. <i>Radiotherapy and Oncology</i> , 2015, 114, 135-137.	0.3	22
175	Independent validation of the prognostic value of cancer stem cell marker expression and hypoxia-induced gene expression for patients with locally advanced HNSCC after postoperative radiotherapy. <i>Clinical and Translational Radiation Oncology</i> , 2016, 1, 19-26.	0.9	22
176	Characterization of a switchable chimeric antigen receptor platform in a pre-clinical solid tumor model. <i>Oncolmmunology</i> , 2017, 6, e1342909.	2.1	22
177	German Cancer Consortium ( DKTK ) – A national consortium for translational cancer research. <i>Molecular Oncology</i> , 2019, 13, 535-542.	2.1	22
178	What will radiation oncology look like in 2050? A look at a changing professional landscape in Europe and beyond. <i>Molecular Oncology</i> , 2020, 14, 1577-1585.	2.1	22
179	Evaluation of response using FDG-PET/CT and diffusion weighted MRI after radiochemotherapy of pancreatic cancer: a non-randomized, monocentric phase III clinical trial – PaCa-DD-041 (Eudra-CT) Tj ETQq1 1 0.784314 rgBT /Overlo	1.0	21
180	Impact of Hypoxia and the Metabolic Microenvironment on Radiotherapy of Solid Tumors. <i>Strahlentherapie Und Onkologie</i> , 2004, 180, 609-615.	1.0	21

#	ARTICLE	IF	CITATIONS
181	Radiation-induced lung damage – Clinical risk profiles and predictive imaging on their way to risk-adapted individualized treatment planning?. <i>Radiotherapy and Oncology</i> , 2015, 117, 1-3.	0.3	21
182	EGFR-amplification plus gene expression profiling predicts response to combined radiotherapy with EGFR-inhibition: A preclinical trial in 10 HNSCC-tumour-xenograft models. <i>Radiotherapy and Oncology</i> , 2017, 124, 496-503.	0.3	21
183	Recovery from sublethal damage during fractionated irradiation of human FaDu SCC. <i>Radiotherapy and Oncology</i> , 2005, 74, 331-336.	0.3	20
184	PAI-1 levels predict response to fractionated irradiation in 10 human squamous cell carcinoma lines of the head and neck. <i>Radiotherapy and Oncology</i> , 2008, 86, 361-368.	0.3	20
185	PRONTOX – proton therapy to reduce acute normal tissue toxicity in locally advanced non-small-cell lung carcinomas (NSCLC): study protocol for a randomised controlled trial. <i>Trials</i> , 2016, 17, 543.	0.7	20
186	In vivo imaging in the oral cavity by endoscopic optical coherence tomography. <i>Journal of Biomedical Optics</i> , 2018, 23, 1.	1.4	20
187	A Questionnaire Study to Assess the Value of the Vulnerable Elders Survey, G8, and Predictors of Toxicity as Screening Tools for Frailty and Toxicity in Geriatric Cancer Patients. <i>Oncology Research and Treatment</i> , 2016, 39, 210-216.	0.8	19
188	Optimizing clinical research and generating prospective high-quality data in particle therapy in Europe: Introducing the European Particle Therapy Network (EPTN). <i>Radiotherapy and Oncology</i> , 2018, 128, 1-3.	0.3	19
189	Comprehensive Analysis of Tumour Sub-Volumes for Radiomic Risk Modelling in Locally Advanced HNSCC. <i>Cancers</i> , 2020, 12, 3047.	1.7	19
190	The use of a comprehensive tumour xenograft dataset to validate gene signatures relevant for radiation response. <i>Radiotherapy and Oncology</i> , 2009, 92, 417-422.	0.3	18
191	Establishment of a small animal tumour model for in vivo studies with low energy laser accelerated particles. <i>Radiation Oncology</i> , 2014, 9, 57.	1.2	18
192	Increase in Tumor Control and Normal Tissue Complication Probabilities in Advanced Head-and-Neck Cancer for Dose-Escalated Intensity-Modulated Photon and Proton Therapy. <i>Frontiers in Oncology</i> , 2015, 5, 256.	1.3	18
193	Ex vivo $\gamma$ H2AX radiation sensitivity assay in prostate cancer: Inter-patient and intra-patient heterogeneity. <i>Radiotherapy and Oncology</i> , 2017, 124, 386-394.	0.3	18
194	Modeling <i>in vivo</i> relative biological effectiveness in particle therapy for clinically relevant endpoints. <i>Acta Oncologica</i> , 2017, 56, 1392-1398.	0.8	18
195	Effect of the Hypoxic Cell Sensitizer Isometronidazole on Local Control of Two Human Squamous Cell Carcinomas after Fractionated Irradiation. <i>Strahlentherapie Und Onkologie</i> , 2004, 180, 375-382.	1.0	17
196	Ultrafractionation does not Improve the Results of Radiotherapy in Radioresistant Murine DDL1 Lymphoma. <i>Strahlentherapie Und Onkologie</i> , 2005, 181, 540-544.	1.0	17
197	The future of IGRT – Cost Benefit Analysis. <i>Acta Oncologica</i> , 2008, 47, 1188-1192.	0.8	17
198	Comparison of $^{18}F$ FDG uptake and distribution with hypoxia and proliferation in FaDu human squamous cell carcinoma (hSCC) xenografts after single dose irradiation. <i>International Journal of Radiation Biology</i> , 2009, 85, 772-780.	1.0	17

#	ARTICLE	IF	CITATIONS
199	Usefulness of dynamic contrast enhanced computed tomography in patients with non-small-cell lung cancer scheduled for radiation therapy. <i>Lung Cancer</i> , 2010, 70, 280-285.	0.9	17
200	Be smart against cancer! A school-based program covering cancer-related risk behavior. <i>BMC Public Health</i> , 2014, 14, 392.	1.2	17
201	Comparison of detection methods for HPV status as a prognostic marker for loco-regional control after radiochemotherapy in patients with HNSCC. <i>Radiotherapy and Oncology</i> , 2018, 127, 27-35.	0.3	17
202	Concept for individualized patient allocation: ReCompare™ remote comparison of particle and photon treatment plans. <i>Radiation Oncology</i> , 2014, 9, 59.	1.2	16
203	SDF-1/CXCR4 expression in head and neck cancer and outcome after postoperative radiochemotherapy. <i>Clinical and Translational Radiation Oncology</i> , 2017, 5, 28-36.	0.9	16
204	Rapid re-expression of CD133 protein in colorectal cancer cell lines in vitro and in vivo. <i>Laboratory Investigation</i> , 2012, 92, 1607-1622.	1.7	15
205	Cancer Core Europe: A European cancer research alliance realizing a research infrastructure with critical mass and programmatic approach to cure cancer in the 21st century. <i>European Journal of Cancer</i> , 2018, 103, 155-159.	1.3	15
206	Final Results of the Prospective Biomarker Trial PETra: [11C]-MET-Accumulation in Postoperative PET/MRI Predicts Outcome after Radiochemotherapy in Glioblastoma. <i>Clinical Cancer Research</i> , 2021, 27, 1351-1360.	3.2	15
207	Keynote comment: Radiotherapy in the age of molecular oncology. <i>Lancet Oncology</i> , The, 2006, 7, 786-787.	5.1	14
208	Impact of exogenous lactate on survival and radioresponse of carcinoma cells in vitro. <i>International Journal of Radiation Biology</i> , 2009, 85, 989-1001.	1.0	14
209	Reproducibility of target coverage in stereotactic spot scanning proton lung irradiation under high frequency jet ventilation. <i>Radiotherapy and Oncology</i> , 2013, 109, 45-50.	0.3	14
210	Simultaneous PLK1 inhibition improves local tumour control after fractionated irradiation. <i>Radiotherapy and Oncology</i> , 2013, 108, 422-428.	0.3	14
211	Inactivation of HNSCC Cells by 90Y-Labeled Cetuximab Strictly Depends on the Number of Induced DNA Double-Strand Breaks. <i>Journal of Nuclear Medicine</i> , 2013, 54, 416-423.	2.8	14
212	FMISO-PET-based lymph node hypoxia adds to the prognostic value of tumor only hypoxia in HNSCC patients. <i>Radiotherapy and Oncology</i> , 2019, 130, 97-103.	0.3	14
213	The COVID-19 Pandemic and Cancer Patients in Germany: Impact on Treatment, Follow-Up Care and Psychological Burden. <i>Frontiers in Public Health</i> , 2021, 9, 788598.	1.3	14
214	Metastases after fractionated radiation therapy of three murine tumor models. <i>International Journal of Radiation Oncology Biology Physics</i> , 1990, 19, 367-370.	0.4	13
215	No evidence for a different magnitude of the time factor for continuously fractionated irradiation and protocols including gaps in two human squamous cell carcinoma in nude mice. <i>Radiotherapy and Oncology</i> , 2001, 59, 187-194.	0.3	13
216	Core needle biopsies for determination of the microenvironment in individual tumours for longitudinal radiobiological studies. <i>Radiotherapy and Oncology</i> , 2009, 92, 460-465.	0.3	13

#	ARTICLE	IF	CITATIONS
217	Haemoglobin and creatinine values as prognostic factors for outcome of concurrent radiochemotherapy in locally advanced head and neck cancers. <i>Strahlentherapie Und Onkologie</i> , 2016, 192, 552-560.	1.0	13
218	Comparison of the Response of human FaDu squamous cell carcinoma in nude mice after hypofractionated-accelerated regimens and "curative" fractionation schedules. <i>Strahlentherapie Und Onkologie</i> , 1998, 174, 315-319.	1.0	12
219	Correlating quantitative MR measurements of standardized tumor lines with histological parameters and tumor control dose. <i>Radiotherapy and Oncology</i> , 2010, 96, 123-130.	0.3	12
220	What next?. <i>Radiotherapy and Oncology</i> , 2014, 110, 1-2.	0.3	12
221	Personalized Radiation Oncology: Epidermal Growth Factor Receptor and Other Receptor Tyrosine Kinase Inhibitors. <i>Recent Results in Cancer Research</i> , 2016, 198, 107-122.	1.8	12
222	Toward Distributed Conduction of Large-Scale Studies in Radiation Therapy and Oncology: Open-Source System Integration Approach. <i>IEEE Journal of Biomedical and Health Informatics</i> , 2016, 20, 1397-1403.	3.9	12
223	Increased FDG uptake on late-treatment PET in non-tumour-affected oesophagus is prognostic for pathological complete response and disease recurrence in patients undergoing neoadjuvant radiochemotherapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1813-1822.	3.3	12
224	The clinical target volume in lung, head-and-neck, and esophageal cancer: Lessons from pathological measurement and recurrence analysis. <i>Clinical and Translational Radiation Oncology</i> , 2017, 3, 1-8.	0.9	12
225	Pre-clinical imaging for establishment and comparison of orthotopic non-small cell lung carcinoma: in search for models reflecting clinical scenarios. <i>British Journal of Radiology</i> , 2019, 92, 20180539.	1.0	12
226	Dose dependent cerebellar atrophy in glioma patients after radio(chemo)therapy. <i>Radiotherapy and Oncology</i> , 2020, 150, 262-267.	0.3	12
227	Radiotherapy enhances uptake and efficacy of 90Y-cetuximab: A preclinical trial. <i>Radiotherapy and Oncology</i> , 2021, 155, 285-292.	0.3	12
228	Ultrafractionation in human malignant glioma xenografts. <i>International Journal of Cancer</i> , 2003, 107, 333-333.	2.3	11
229	Tumour-infiltrating CD11b+ myelomonocytes and response to fractionated irradiation of human squamous cell carcinoma (hSCC) xenografts. <i>Radiotherapy and Oncology</i> , 2011, 101, 80-85.	0.3	11
230	Place of Proton Radiotherapy in Future Radiotherapy Practice. <i>Seminars in Radiation Oncology</i> , 2013, 23, 149-153.	1.0	11
231	Proton radiography for inline treatment planning and positioning verification of small animals. <i>Acta Oncologica</i> , 2017, 56, 1399-1405.	0.8	11
232	Tumor heterogeneity determined with a $\gamma$ H2AX foci assay: A study in human head and neck squamous cell carcinoma (hHNSCC) models. <i>Radiotherapy and Oncology</i> , 2017, 124, 379-385.	0.3	11
233	Comparable radiation response of ex vivo and in vivo irradiated tumor samples determined by residual $\gamma$ H2AX. <i>Radiotherapy and Oncology</i> , 2019, 139, 94-100.	0.3	11
234	Early and late side effects, dosimetric parameters and quality of life after proton beam therapy and IMRT for prostate cancer: a matched-pair analysis. <i>Acta Oncologica</i> , 2019, 58, 916-925.	0.8	11

#	ARTICLE	IF	CITATIONS
235	New Targets for the Modulation of Radiation Response - Selective Inhibition of the Enzyme Cyclooxygenase 2. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2003, 3, 354-359.	7.0	11
236	Present Results of Neutron Therapy: The German experience. <i>Acta Oncologica</i> , 1994, 33, 281-287.	0.8	10
237	Regionales Brustzentrum am Universitäts-Krebszentrum Dresden. <i>Breast Care</i> , 2008, 3, 11-11.	0.8	10
238	Towards clinical evidence in particle therapy: ENLIGHT, PARTNER, ULICE and beyond. <i>Journal of Radiation Research</i> , 2013, 54, i6-i12.	0.8	10
239	Application of organ tolerance dose-constraints in clinical studies in radiation oncology. <i>Strahlentherapie Und Onkologie</i> , 2014, 190, 621-627.	1.0	10
240	FDG uptake in normal tissues assessed by PET during treatment has prognostic value for treatment results in head and neck squamous cell carcinomas undergoing radiochemotherapy. <i>Radiotherapy and Oncology</i> , 2017, 122, 437-444.	0.3	10
241	Residual gammaH2AX foci in head and neck squamous cell carcinomas as predictors for tumour radiosensitivity: Evaluation in pre-clinical xenograft models and clinical specimens. <i>Radiotherapy and Oncology</i> , 2019, 137, 24-31.	0.3	10
242	Comparison of GeneChip, nCounter, and Real-Time PCR-Based Gene Expressions Predicting Locoregional Tumor Control after Primary and Postoperative Radiochemotherapy in Head and Neck Squamous Cell Carcinoma. <i>Journal of Molecular Diagnostics</i> , 2020, 22, 801-810.	1.2	10
243	Results of a randomized controlled phase III trial: efficacy of polyphenol-containing cystus® tea mouthwash solution for the reduction of mucositis in head and neck cancer patients undergoing external beam radiotherapy. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 63-73.	1.0	10
244	Screening and Validation of Molecular Targeted Radiosensitizers. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, e63-e74.	0.4	10
245	Therapy of localized non-small cell lung cancer (take home messages). <i>Lung Cancer</i> , 2001, 33, S47-S49.	0.9	9
246	Towards equity in turbulent Europe. <i>Radiotherapy and Oncology</i> , 2005, 75, 251-252.	0.3	9
247	Clonogens and cancer stem cells. <i>Nature Reviews Cancer</i> , 2008, 8, 990-990.	12.8	9
248	Sun Protection Training Based on a Theater Play for Preschoolers: an Effective Method for Imparting Knowledge on Sun Protection?. <i>Journal of Cancer Education</i> , 2013, 28, 435-438.	0.6	9
249	Effect of combined irradiation and EGFR/Erb-B inhibition with BIBW 2992 on proliferation and tumour cure in cell lines and xenografts. <i>Radiation Oncology</i> , 2014, 9, 261.	1.2	9
250	Implementation of a software for Remote Comparison of Particle and photon treatment plans: ReCompare. <i>Zeitschrift Fur Medizinische Physik</i> , 2015, 25, 287-294.	0.6	9
251	Sites of recurrent disease and prognostic factors in SCLC patients treated with radiochemotherapy. <i>Clinical and Translational Radiation Oncology</i> , 2017, 7, 36-42.	0.9	9
252	Correlation between FMISO-PET based hypoxia in the primary tumour and in lymph node metastases in locally advanced HNSCC patients. <i>Clinical and Translational Radiation Oncology</i> , 2019, 15, 108-112.	0.9	9

#	ARTICLE	IF	CITATIONS
253	Establishment and Characterisation of Heterotopic Patient-Derived Xenografts for Glioblastoma. <i>Cancers</i> , 2020, 12, 871.	1.7	9
254	Tyrosine Kinase c-MET as Therapeutic Target for Radiosensitization of Head and Neck Squamous Cell Carcinomas. <i>Cancers</i> , 2021, 13, 1865.	1.7	9
255	Comparison of the composition of lymphocyte subpopulations in non-relapse and relapse patients with squamous cell carcinoma of the head and neck before, during radiochemotherapy and in the follow-up period: a multicenter prospective study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG). <i>Radiation Oncology</i> , 2021, 16, 141.	1.2	9
256	The Impact of Cell-Cell Contact, E-Cadherin and EGF Receptor on the Cellular Radiosensitivity of A431 Cancer Cells. <i>Radiation Research</i> , 2012, 178, 224-233.	0.7	8
257	Cytotoxic properties of radionuclide-conjugated Cetuximab without and in combination with external irradiation in head and neck cancer cells in vitro. <i>International Journal of Radiation Biology</i> , 2014, 90, 678-686.	1.0	8
258	Impact of pre- and early per-treatment FDG-PET based dose-escalation on local tumour control in fractionated irradiated FaDu xenograft tumours. <i>Radiotherapy and Oncology</i> , 2016, 121, 447-452.	0.3	8
259	Vertebral fractures – An underestimated side-effect in patients treated with radio(chemo)therapy. <i>Radiotherapy and Oncology</i> , 2016, 118, 421-423.	0.3	8
260	Definition and validation of a radiomics signature for loco-regional tumour control in patients with locally advanced head and neck squamous cell carcinoma. <i>Clinical and Translational Radiation Oncology</i> , 2021, 26, 62-70.	0.9	8
261	Dual role of ER stress in response to metabolic co-targeting and radiosensitivity in head and neck cancer cells. <i>Cellular and Molecular Life Sciences</i> , 2021, 78, 3021-3044.	2.4	8
262	Radiation oncology in the new virtual and digital era. <i>Radiotherapy and Oncology</i> , 2021, 154, A1-A4.	0.3	8
263	Identification of patient benefit from proton beam therapy in brain tumour patients based on dosimetric and NTCP analyses. <i>Radiotherapy and Oncology</i> , 2021, 160, 69-77.	0.3	8
264	Impact of Tumor Stroma on Expression of the Tumor Bed Effect in R1H Rat Rhabdomyosarcoma. <i>Radiation Research</i> , 1994, 140, 432.	0.7	7
265	Shaping the future: training of professionals for radiotherapy in Europe. <i>Radiotherapy and Oncology</i> , 2004, 70, 103-105.	0.3	7
266	Adoptive transfer of cytotoxic T-cells for treatment of residual disease after irradiation. <i>International Journal of Radiation Biology</i> , 2007, 83, 827-836.	1.0	7
267	Inactivation of AP1 Proteins by a Nuclear Serine Protease Precedes the Onset of Radiation-Induced Fibrosing Alveolitis1. <i>Radiation Research</i> , 2008, 169, 531-542.	0.7	7
268	Long-term quality of life in inoperable non-small cell lung cancer patients treated with conventionally fractionated compared to hyperfractionated accelerated radiotherapy – Results of the randomized CHARTWEL trial. <i>Radiotherapy and Oncology</i> , 2018, 126, 283-290.	0.3	7
269	The Porto European Cancer Research Summit 2021. <i>Molecular Oncology</i> , 2021, 15, 2507-2543.	2.1	7
270	Modified fractionation. , 2009, , 135-148.		7



#	ARTICLE	IF	CITATIONS
271	Personalised radiation therapy taking both the tumour and patient into consideration. <i>Radiotherapy and Oncology</i> , 2022, 166, A1-A5.	0.3	7
272	TCP and NTCP in preclinical and clinical research in Europe. <i>Rays</i> , 2005, 30, 121-6.	0.2	7
273	Local Control after Locally Ablative, Image-Guided Radiotherapy of Oligometastases Identified by Gallium-68-PSMA-Positron Emission Tomography in Castration-Sensitive Prostate Cancer Patients (OLI-P). <i>Cancers</i> , 2022, 14, 2073.	1.7	7
274	Fractionation Effect on Radiation-Induced Growth Retardation of Tibia in Rabbits and Rats. <i>Acta Oncologica</i> , 1998, 37, 151-158.	0.8	6
275	Hyperfractionated radiotherapy: Tops or flops?. , 1999, 33, 399-402.		6
276	Portal Verification of High-Energy Electron Beams Using their Photon Contamination by Film-Cassette Systems. <i>Strahlentherapie Und Onkologie</i> , 2006, 182, 37-44.	1.0	6
277	Translational research in radiotherapy â€“ Getting closer to the bedside. <i>Radiotherapy and Oncology</i> , 2007, 83, 217-219.	0.3	6
278	Experimental Evaluation of Functional Imaging for Radiotherapy. <i>Strahlentherapie Und Onkologie</i> , 2007, 183, 41-42.	1.0	6
279	Union of light ion therapy centers in Europe (ULICE EC FP7) â€“ Objectives and achievements of joint research activities. <i>Radiotherapy and Oncology</i> , 2018, 128, 83-100.	0.3	6
280	Biomedical Research Goes Viral: Dangers and Opportunities. <i>Cell</i> , 2020, 181, 1189-1193.	13.5	6
281	Combined tumor plus nontumor interim FDGâ€“PET parameters are prognostic for response to chemoradiation in squamous cell esophageal cancer. <i>International Journal of Cancer</i> , 2020, 147, 1427-1436.	2.3	6
282	ERCC2 gene single-nucleotide polymorphism as a prognostic factor for locally advanced head and neck carcinomas after definitive cisplatin-based radiochemotherapy. <i>Pharmacogenomics Journal</i> , 2021, 21, 37-46.	0.9	6
283	Modelling of late side-effects following cranial proton beam therapy. <i>Radiotherapy and Oncology</i> , 2021, 157, 15-23.	0.3	6
284	Tumor Biologyâ€™s Impact on Clinical Cure Rates. <i>Medical Radiology</i> , 2009, , 323-334.	0.0	6
285	Physical and Technical Quality Assurance in the CHARTWEL-Bronchus Trial. <i>Strahlentherapie Und Onkologie</i> , 2003, 179, 152-157.	1.0	5
286	In regard to Solomon et al.: EGFR blockade with ZD1839 (â€œressaâ€œ) potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. <i>IJROBP</i> 2003;55:713â€“723. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 57, 300-301.	0.4	5
287	Monitoring PAI-1 and VEGF Levels in 6 Human Squamous Cell Carcinoma Xenografts During Fractionated Irradiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, e409-e417.	0.4	5
288	Molecular radiation biology/oncology at its best: Cutting edge research presented at the 13th International Wolfsberg Meeting on Molecular Radiation Biology/Oncology. <i>Radiotherapy and Oncology</i> , 2013, 108, 357-361.	0.3	5

#	ARTICLE	IF	CITATIONS
289	Modeling tumor control probability for spatially inhomogeneous risk of failure based on clinical outcome data. <i>Zeitschrift Fur Medizinische Physik</i> , 2017, 27, 285-299.	0.6	5
290	The world needs new knowledge. <i>Radiotherapy and Oncology</i> , 2018, 126, 1-2.	0.3	5
291	Retrospective investigation of the prognostic value of the $\alpha$ 21 integrin expression in patients with head and neck squamous cell carcinoma receiving primary radio(chemo)therapy. <i>PLoS ONE</i> , 2018, 13, e0209479.	1.1	5
292	Heterogeneity of $\gamma$ H2AX Foci Increases in Ex Vivo Biopsies Relative to In Vivo Tumors. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2616.	1.8	5
293	Towards a Cancer Mission in Horizon Europe. <i>Molecular Oncology</i> , 2019, 13, 2301-2304.	2.1	5
294	Boosting the social impact of innovative cancer research – towards a mission-oriented approach to cancer. <i>Molecular Oncology</i> , 2019, 13, 497-501.	2.1	5
295	Dose-volume predictors of early esophageal toxicity in non-small cell lung cancer patients treated with accelerated-hyperfractionated radiotherapy. <i>Radiotherapy and Oncology</i> , 2020, 143, 44-50.	0.3	5
296	Radiotherapy & Oncology during the COVID-19 pandemic. <i>Radiotherapy and Oncology</i> , 2020, 146, 221-222.	0.3	5
297	Four decades with ESTRO. <i>Radiotherapy and Oncology</i> , 2020, 142, 1-5.	0.3	5
298	Generation of biological hypotheses by functional imaging links tumor hypoxia to radiation induced tissue inflammation/glucose uptake in head and neck cancer. <i>Radiotherapy and Oncology</i> , 2021, 155, 204-211.	0.3	5
299	Local Control as an End Point in Experimental Radiation Therapy of Human Tumor Xenografts. <i>Contributions To Oncology / Beitrage Zur Onkologie</i> , 1996, , 154-160.	0.1	5
300	Combined radiotherapy and chemotherapy. , 2009, , 246-258.		5
301	Moving Beyond the Standard of Care: Accelerate Testing of Radiation-Drug Combinations. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 1131-1139.	0.4	5
302	Analyses of molecular subtypes and their association to mechanisms of radioresistance in patients with HPV-negative HNSCC treated by postoperative radiochemotherapy. <i>Radiotherapy and Oncology</i> , 2022, 167, 300-307.	0.3	5
303	Biomarker signatures for primary radiochemotherapy of locally advanced HNSCC – Hypothesis generation on a multicentre cohort of the DTKK-ROG. <i>Radiotherapy and Oncology</i> , 2022, 169, 8-14.	0.3	5
304	In Vivo Verification of Electron Beam Energy by Patient Exit Dose and Optical Density of Portal Films. <i>Strahlentherapie Und Onkologie</i> , 2004, 180, 62-65.	1.0	4
305	Bridging the valley of death: The new Radiotherapy & Oncology section – First in man – Translational innovations in radiation oncology – <i>Radiotherapy and Oncology</i> , 2016, 118, 217-219.	0.3	4
306	Sample-size calculation for preclinical dose-response experiments using heterogeneous tumour models. <i>Radiotherapy and Oncology</i> , 2021, 158, 262-267.	0.3	4

#	ARTICLE	IF	CITATIONS
307	Molecular Response to Combined Molecular- and External Radiotherapy in Head and Neck Squamous Cell Carcinoma (HNSCC). <i>Cancers</i> , 2021, 13, 5595.	1.7	4
308	Development and validation of a 6-gene signature for the prognosis of loco-regional control in patients with HPV-negative locally advanced HNSCC treated by postoperative radio(chemo)therapy. <i>Radiotherapy and Oncology</i> , 2022, 171, 91-100.	0.3	4
309	Radiotherapy in small cell lung cancer: Limited volumes in limited disease and adding thoracic radiotherapy in extended disease?. <i>Radiotherapy and Oncology</i> , 2012, 102, 165-167.	0.3	3
310	Clinical trials for personalized glioblastoma radiotherapy: Markers for efficacy and late toxicity but often delayed treatment – Does that matter?. <i>Radiotherapy and Oncology</i> , 2016, 118, 211-213.	0.3	3
311	Continuously getting a bit more picky. <i>Radiotherapy and Oncology</i> , 2019, 130, 1.	0.3	3
312	Value of functional in-vivo endpoints in preclinical radiation research. <i>Radiotherapy and Oncology</i> , 2021, 158, 155-161.	0.3	3
313	Molecular-targeted agents for enhancing tumour response. , 2009, , 287-300.		3
314	<sup>18</sup> F-Fluorodeoxyglucose Positron Emission Tomography of Head and Neck Cancer: Location and HPV Specific Parameters for Potential Treatment Individualization. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
315	Comparison of patient stratification by computed tomography radiomics and hypoxia positron emission tomography in head-and-neck cancer radiotherapy. <i>Physics and Imaging in Radiation Oncology</i> , 2020, 15, 52-59.	1.2	2
316	Bildung und Steuerung des Universitäts KrebsCentrum Dresden. , 2017, , 639-649.		2
317	Stem cells in radiotherapy. , 2018, , 171-181.		2
318	HPV and beyond-looking out for biomarkers for distinguishing the good prognosis from the bad prognosis group in locally advanced and clinically high risk HNSCC. <i>Annals of Translational Medicine</i> , 2015, 3, 255.	0.7	2
319	Tumor DNA-Methylome derived Epigenetic Fingerprint Identifies HPV –negative Head and Neck Patients at Risk for Locoregional Recurrence after Postoperative Radiochemotherapy. <i>International Journal of Cancer</i> , 2021, 150, 603.	2.3	2
320	A Novel 2-Metagene Signature to Identify High-Risk HNSCC Patients amongst Those Who Are Clinically at Intermediate Risk and Are Treated with PORT. <i>Cancers</i> , 2022, 14, 3031.	1.7	2
321	Wild-Type Sequence of TP53, Intron 7. <i>Radiation Research</i> , 2001, 155, 641-641.	0.7	1
322	Selection of Genetically Distinct, Rapidly Proliferating Clones does not Contribute to Repopulation during Fractionated Irradiation in FaDu Squamous Cell Carcinoma. <i>Radiation Research</i> , 2003, 160, 257-262.	0.7	1
323	Imaging radiation biology for optimised radiation therapy. <i>International Journal of Radiation Biology</i> , 2009, 85, 729-731.	1.0	1
324	Fractionation Concepts. <i>Medical Radiology</i> , 2016, , 17-34.	0.0	1

#	ARTICLE	IF	CITATIONS
325	Radiation Oncology – Towards a mission-oriented approach to cancer. <i>Molecular Oncology</i> , 2020, 14, 1429-1430.	2.1	1
326	Solving problems is smart, preventing them is wise: Lessons learned from the 2nd International DKFZ Conference on Cancer Prevention. <i>International Journal of Cancer</i> , 2021, 148, 3086-3096.	2.3	1
327	Preclinical In Vivo Evaluation of Novel Radiosensitizers by Local Tumor Control Experiments. <i>Cancer Drug Discovery and Development</i> , 2020, , 137-159.	0.2	1
328	Importance of long-term follow up to address long-term effectiveness and toxicity of radiotherapy. <i>Radiotherapy and Oncology</i> , 2022, 170, 1-3.	0.3	1
329	Response to Lindstrom and Fowler's –the influence of dose and time on local control of carcinoma of the larynx by radiation therapy–. <i>International Journal of Radiation Oncology Biology Physics</i> , 1992, 22, 1163.	0.4	0
330	Transferring university knowledge to develop new technologies: the model of the "OncoRay – Joint Center for Radiation Research in Oncology". <i>International Journal of Healthcare Technology and Management</i> , 2010, 11, 328.	0.1	0
331	Fractionation Concepts. <i>Medical Radiology</i> , 2010, , 13-26.	0.0	0
332	Corrigendum to –HPV16 DNA status is a strong prognosticator of loco-regional control after postoperative radiochemotherapy of locally advanced oropharyngeal carcinoma: Results from a multicentre explorative study of the German Cancer Consortium Radiation Oncology Group (DKTK-ROG)–. <i>Radiother. Oncol.</i> 113 (2014) 317–323]. <i>Radiotherapy and Oncology</i> , 2015, 114, 419.	0.3	0
333	The Role of Cancer Stem Cells in Tumour Radioresponse. , 2016, , 43-74.		0
334	Farewell to Prof. Jens Overgaard. <i>Radiotherapy and Oncology</i> , 2017, 122, 1.	0.3	0
335	Session 39: Modelling and simulation III. <i>Biomedizinische Technik</i> , 2017, 62, .	0.9	0
336	Advances in Radiation Oncology. , 2018, , .		0
337	Tribute to David Thwaites. <i>Radiotherapy and Oncology</i> , 2020, 153, 5-6.	0.3	0
338	In reply to the Letter to the Editor by Chen and Lui regarding –Radiotherapy enhances uptake and efficacy of 90Y-cetuximab: A preclinical trial– by A Dietrich et al.. <i>Radiotherapy and Oncology</i> , 2021, 161, 261-262.	0.3	0
339	3D Semi-quantification of Nanoparticle Content in Tissue on Experimental and Commercial ¼CT-Scanner. <i>Springer Proceedings in Physics</i> , 2012, , 111-115.	0.1	0
340	Cancer: Education and Primary Prevention Starts in Childhood and Adolescence. <i>Journal of Cancer Therapy</i> , 2016, 07, 851-856.	0.1	0
341	Response to comment on –Biomarker signatures for primary radiochemotherapy of locally advanced HNSCC–. <i>Radiotherapy and Oncology</i> , 2022, , .	0.3	0
342	Subjective memory impairment in glioma patients with curative radiotherapy. <i>Radiotherapy and Oncology</i> , 2022, , .	0.3	0